

Welcome to **Pharmaceutical Outsourcing Website** - Read [Articles](#), find [new services & companies](#), browse [Industry news](#), tell us what you think on [Twitter](#) and [Facebook](#). Keep up to date by [subscribing to the magazine](#) or [newsletter!](#)

Welcome Guest [Sign In](#) [Register](#) [Subscribe](#)

Pharmaceutical Outsourcing™

Search Pharmaceutical Outsourcing

[Home](#) [API](#) [Manufacturing](#) [Clinical Trials](#) [Analytical Testing](#) [Cold Chain](#) [Company Focus](#)

[Articles](#) [News](#) [Events](#) [Videos](#) [White Papers/Application Notes](#) [Posters](#) [Research](#) [Issue Archives](#)

[Articles](#) [Article Archives](#) [What Could Possibly Go Wrong in API Development?](#)

What Could Possibly Go Wrong in API Development?

Posted: March 20, 2018

Tweet [Share 0](#) [Share](#) [Email](#) [Print](#) [Comments](#)

By: [Ed Price](#)

· [PCI Synthesis](#)

It's Not So Much What Happens But How You Handle It

The quality of [Active Pharmaceutical Ingredients](#) (APIs) has a significant effect on the efficacy and safety of medications, and as such, poorly manufactured or compromised APIs can result in serious issues, such as illnesses or even death.

Since APIs are essentially the lifeblood of commercial drugs, the number-one goal of Contract Manufacturing Organizations (CMOs) and pharmaceutical firms is to develop a safe and robust process that will eventually bring the API to market safely, effectively and as quickly as possible.

To accomplish this, the research scientist's job is to identify the process, or development route that is robust, safe and scalable, while also providing a path that leads to the best yield and purity. This route selection is critical. Yet, I would bet that no process chemist – ever – said that the route to drug development and commercialization was easy and without a single bump in the road. As the famous quote goes, "the best laid plans of mice and men often go awry." Sometimes, even with the best route selection, proper testing and method development, problems can occur through no fault of the scientists or the processes.

Six Issues That Can Arise During API Manufacturing – and How to Resolve Them

Unexpected impurities. Sometimes, unknown impurities or a larger-than expected yield of impurities is produced during scale up. The very process of scaling up can produce unexpected results, such as new impurities that weren't present during smaller-scale production or the amount of an impurity can increase significantly. At that point, the R&D team needs to examine each step to determine if they can eliminate or reduce the impurity to the expected level.

Problems with starting materials. A key starting material may not work as intended, so in some cases, the team may need to evaluate the grade or supplier to get the intended results. While it doesn't happen often, sometimes if the initial work was conducted in a different facility or the other provider took short cuts that were not documented, the CMO would need to re-do the process to make sure the results produced are consistent.

The initial process may not be scalable. This would require re-evaluating the process, including determining whether there are mistakes or if the master batch records are sloppy. Another step to take may be to find out if there is larger equipment available that will mimic the R&D size.

Time needed in production. A major focus should be on the stability of the material produced. In the quest to get material to the next step, sometimes teams will avoid asking whether the product is stable enough to be held or if it has the possibility of degrading.



CONNECT WITH US



RELATED CATEGORIES

[API](#) »

[Active Pharmaceutical Ingredient \(API\) Manufacturing Services](#) »

[Active Pharmaceutical Ingredient \(API\) Products and Services](#) »

[Pharmaceutical Formulation Development](#) »

[Pharmaceutical Manufacturing](#) »

FOLLOW PO

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Your Email Address



but if you use the wrong temperature – too high or too low – it could impact the product quality.

Poorly defined Critical Process Parameters (CPPs). CPP refers to a “process parameter whose variability has an impact on a CQA (Critical Quality Attributes) and therefore should be monitored or controlled,” according to the FDA. There are a lot of variables here that need to be evaluated – such as particle size, moisture content, order of addition, filtration method, etc. All of these, if not clearly defined ahead of time, could lead to major issues during scale up.



Discover why we're one of the biggest names in small molecule APIs

Meet our experts



Expect the Unexpected

Unexpected challenges could really be anything from choosing the wrong route and starting over, to getting a great process and in the end being unable to identify the impurities. For these reasons, it's important for the R&D scientist to work closely with the Method Development team to ensure they have analytical methods that can be relied upon and work for their intended use. The scientist may think he has a super product, but once tested it could fail for low assay, residual solvents, impurities, etc.

The R&D team is in charge of determining the starting materials used – from the quality specifications to the vendor they are ordered from. When the process is transferred to GMP, it is important to use the same source and quality of the starting material to ensure consistency. As it is, R&D may run into unexpected issues and problems that need to be solved along the way to ensure a successful technical transfer from the R&D facility to the GMP group. In the land of R&D, the mantra is, expect the unexpected.

A structured approach also requires that companies don't look for shortcuts or ways to streamline the critical processes. The costs associated with the initial routing, familiarization or optimization of a process can be well worth it in the long run, while short cuts may end up costing more and causing unnecessary delays.

The API market is flourishing, thanks to expiring patents on global blockbuster drugs and an increase in the adoption of generics, among other factors. As competition heats up, drug developers and manufacturers need to focus on sound and steady processes and testing, while anticipating that problems can and most likely will occur despite their best efforts. The key is in recognizing the possible challenges and having a game plan in place to quickly get back on course on the road to product commercialization.

Ed Price is President of PCI Synthesis (www.pcisynthesis.com), a pharmaceutical development CMO based in Newburyport, MA and the largest small molecule drug substance manufacturer in New England. PCI Synthesis is also a commercial manufacturer of NCEs, generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a CDMO, PCI Synthesis provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules.

COMMENTS

SCORR IS YOUR *Strategic* ADVANTAGE FIND OUT WHY >

0 Comments Pharmaceutical Outsourcing Login

Recommend Share Sort by Best



Start the discussion...

LOG IN WITH

OR SIGN UP WITH DISQUS

Name

Be the first to comment.

ALSO ON PHARMACEUTICAL OUTSOURCING

The United States Pharmacopeia (USP) New Chapter on the Storage and ...

2 comments • 2 years ago

SONJA HELENA BORGES — Thank you for clarification. It helps me to speak on my courses in Brazil. This discussion is very ...

Third-Party Manufacturing— From Concept to Contract | Pharmaceutical ...

1 comment • 3 years ago

Seema Sharma — Hi Peter, Thanks for sharing thisPharma Third Party Manufacturing companies

When Things Go Wrong: Planning for the Unexpected | Pharmaceutical ...

1 comment • 3 years ago

Dr. Ningaraddi Belavagi — The article is very informative and is very real....All chemists who reads it likes a lot.

Solubility in Pharmaceutical R&D: Predictions and Reality | ...

1 comment • 3 years ago

proofreading editing services — The content of your blog is having a significant form of medical lesson. Mainly, it ...

Subscribe Add Disqus to your site Add Disqus Add Privacy

About PO

- About Us
Contact Us
Press Room
Privacy Policy
Disclaimer

Advertise with Us

- Advertise With Us
Media Kit

Resources

- Issue Archive
Newsletter Archive
Service Directory
API
Manufacturing
Clinical Trials
Analytical Testing
Cold Chain

Subscription

- Subscribe eNewsletters
Subscribe Magazine
Manage Your Print Subscription

Connect with Us

- Write for Us
Facebook
Twitter
LinkedIn
YouTube

Pharmaceutical Outsourcing is the leading review of business and technology for the pharmaceutical industry throughout North America.

See our other sites »

Copyright © 2018 CompareNetworks, Inc. All rights reserved.

